Kimryn Rathmell: Congratulations to Nancy Single on 17 Years of Advancing Cancer Research at Ohio State
Kimryn Rathmell/wexnermedical.osu.edu and Nancy Single/cancer.osu.edu

Kimryn Rathmell: Congratulations to Nancy Single on 17 Years of Advancing Cancer Research at Ohio State

Kimryn Rathmell,CEO of the Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institut, shared on LinkedIn:

“Groundbreaking cancer research doesn’t happen through discovery alone. It takes exceptional people and strong research infrastructure to turn promising ideas into meaningful advances for patients.

That’s why I’m especially pleased to share that Nancy Single, PhD, has been appointed Associate Vice President for Research Administration for the Ohio State University Comprehensive Cancer Center-James Cancer Hospital and  Solove Research Institute (OSUCCC – James).

Over 17 years at Ohio State, Dr. Single has helped build and strengthen many of the research programs and capabilities that underpin our cancer research enterprise. Her leadership has touched Total Cancer Care, ORIEN, our biorepository, Clinical Research Informatics and Data Analytics, and Clinical Research Operations, which she has led since 2010.

In this expanded role, Dr. Single will provide strategic oversight of research operations across the cancer center and join our executive leadership team. She brings deep institutional knowledge, a highly collaborative approach and an unwavering commitment to enabling great science.

Please join me in congratulating Dr. Single on this well-deserved appointment. I’m excited for what her leadership will make possible as we continue building the people, systems and partnerships that move us closer to a cancer-free world.”

David O’Malley, Director for Translational & Clinical Research Partnerships, Leader of Clinical Trial Innovation at the Center for Cancer Innovation, and Professor of Gynecologic Oncology, shared Kimryn Rathmell’s post, adding:

“Good people leading the way. Congratulations, Nancy Single! Seventeen years of building together toward a cancer free world, and the best is ahead.”

You can also read: Cretostimogene Reduces Bladder Cancer Recurrence Risk by 68% in Phase 3 PIVOT-006 Trial

Kimryn Rathmell: Congratulations to Nancy Single on 17 Years of Advancing Cancer Research at Ohio State